Cognoa
Canvas Dx is indicated as an aid in the diagnosis of ASD in patients between the ages 18 months and 5 years old who are at risk of developmental delay.
The company said that its tool was "highly accurate" in a 425-participant study conducted across 14 U.S. sites.
Also: Healthcare analytics company Apixio picks up a new VP of solutions; Eagle Telemedicine hires on a healthcare-system vet as SVP of operations.
Also: Dario Health Corp names Yadin Shemmer and Adam Stern to board of directors, and Hello Health Group taps Hugo Saavedra as next Chief Commerical Officer.
Also: Thomas Jefferson University Hospitals deployed LifeLink's text chatbot; Advantia Health inks deal with West Virginia's WIC program.
The AI-enabled Superpower Glass system was recently shown to improve socialization skills among children with autism spectrum disorder.
Also: MaxQ AI's software to be distributed with Samsung NeuroLogica medical imaging hardware; Boston Children's Hospital's specialists staff 2nd.MD virtual platform.
In May, a pair of studies were published in the journals Autism Research and the Journal of the American Medical Informatics Association (JAMIA) that evaluated Cognoa’s artificial intelligence-based tool for early identification of autism in children.
Palo Alto, California-based Cognoa’s machine learning app for pediatric behavioral health has received categorization from the FDA as a diagnostic medical device for autism, according to an announcement from the company.